Omnio AB

Based in Sweden, Omnio AB specializes in innovative therapies for chronic wound healing, utilizing recombinant plasminogen to enhance natural recovery processes and improve patient outcomes for hard-to-treat conditions. Omnio AB, founded in 2002 and headquartered in Umea, Sweden, focuses on developing therapies for chronic wounds. The firm has successfully completed one funding deal, raising EUR 4. 3 million in May 2025, which will contribute to the company's operational expansion.

The founder's background details are not provided, and there are no mentions of any mergers or subsidiaries associated with the company. Omnio's primary offering is a recombinant plasminogen-based therapy designed to enhance the body's natural wound healing processes, specifically targeting chronic wounds such as diabetic foot ulcers (DFUs). By leveraging plasminogen's biological functions that facilitate tissue regeneration and infection control, Omnio aims to significantly improve care quality for patients with hard-to-heal wounds. The company primarily serves healthcare providers in both European and US markets, addressing the growing demand for effective chronic wound management solutions.

Omnio operates under a B2B model, partnering with healthcare institutions and clinics that treat chronic wounds. Revenue is generated through sales of its plasminogen therapy, tailored to meet the needs of healthcare facilities. This approach allows the company to deliver a compelling value proposition, particularly in cases where traditional treatments have failed. In May 2025, Omnio AB raised EUR 4.

3 million in venture funding, which will be utilized for manufacturing process enhancements, workforce expansion, and preparation for clinical trials. The company is focusing on upcoming product developments aimed at improving chronic wound therapies. Additionally, Omnio plans to expand into new geographic markets, specifically targeting increased outreach within Europe and the United States as part of their growth strategy.